Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer.

A key enzyme involved in the production of potentially carcinogenic estrogen metabolites and the activation of environmental carcinogens is cytochrome P450 1B1 (CYP1B1), the predominant member of the CYP1 family expressed in normal breast tissue and breast cancer. Because of the preeminent role of CYP1B1 in mammary estrogen/carcinogen metabolism, we examined the CYP1B1 gene to determine whether genetic differences could account for interindividual differences in breast cancer risk. We focused on exon 3, because it encodes the catalytically important heme binding domain of the enzyme, and discovered three polymorphisms of which two are associated with amino acid substitutions in codons 432 (Val-->Leu) and 453 (Asn-->Ser), designated as m1 and m2, respectively. Approximately 40% of Caucasian women have the m1 Val allele compared with nearly 70% of African-American women (P < 0.0001). The allele frequency also differs significantly in m2, with the rare Ser allele being present in 17.4% of Caucasians but only in 3.4% of African Americans (P < 0.0003). To determine whether the polymorphic CYP1B1 alleles hold implications as potential breast cancer risk factors, we compared the CYP1B1 genotypes in 164 Caucasian and 59 African-American breast cancer cases with those in age-, race-, and frequency-matched controls. Odds ratio calculations failed to show a significant association between any of the genotypes and breast cancer. Because CYP1B1 is known to be involved in mammary estrogen metabolism, we investigated whether the estrogen receptor status is influenced by the CYP1B1 genotypes. Caucasian patients with the m1 Val/Val genotype have a significantly higher percentage of estrogen receptor-positive (P = 0.02) and progesterone receptor-positive breast cancers (P = 0.003). There was no correlation with the m2 genotypes. These data suggest that the CYP1B1 polymorphisms in exon 3 are not associated with increased breast cancer risk but that the m1 polymorphism may be functionally important for steroid receptor expression in breast cancer of Caucasian patients.

[1]  J. Lupski,et al.  Mutations in CYP1B1, the gene for cytochrome P4501B1, are the predominant cause of primary congenital glaucoma in Saudi Arabia. , 1998, American journal of human genetics.

[2]  N. Roodi,et al.  Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. , 1998, Cancer research.

[3]  M. Sarfarazi,et al.  Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. , 1997, Human molecular genetics.

[4]  K. Keyomarsi,et al.  Expression of cytochromes P450 in human breast tissue and tumors. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[5]  H. Yamazaki,et al.  Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. , 1996, Cancer research.

[6]  J. Liehr,et al.  4-Hydroxylation of estrogens as marker of human mammary tumors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Yager Jd,et al.  Molecular Mechanisms of Estrogen Carcinogenesis , 1996 .

[8]  J. Yager,et al.  Molecular mechanisms of estrogen carcinogenesis. , 1996, Annual review of pharmacology and toxicology.

[9]  P. Chambon,et al.  In vivo functional analysis of the mouse estrogen receptor gene promoter: a transgenic mouse model to study tissue-specific and developmental regulation of estrogen receptor gene transcription. , 1995, Molecular endocrinology.

[10]  S. Joslyn.  Racial differences in survival from breast cancer. , 1995, JAMA.

[11]  C K Redmond,et al.  Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. , 1994, JAMA.

[12]  K. Buetow,et al.  Genetics of CYP1A1: coamplification of specific alleles by polymerase chain reaction and association with breast cancer. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[13]  E. Jabs,et al.  Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. , 1994, The Journal of biological chemistry.

[14]  J. Gorski,et al.  Involvement of the coding sequence for the estrogen receptor gene in autologous ligand-dependent down-regulation. , 1993, Molecular endocrinology.

[15]  E. Taioli,et al.  A novel CYP1A1 gene polymorphism in African-Americans. , 1993, Carcinogenesis.

[16]  E. Schuetz,et al.  17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1A1: a comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. , 1992, Archives of biochemistry and biophysics.

[17]  T. Aoyama,et al.  Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. , 1991, Archives of biochemistry and biophysics.

[18]  B. Katzenellenbogen,et al.  Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists, and growth factors. , 1989, Molecular endocrinology.

[19]  Li Jj,et al.  Estrogen carcinogenesis in Syrian hamster tissues: role of metabolism. , 1987 .

[20]  N. Breslow,et al.  The analysis of case-control studies , 1980 .